7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Rubin J et al. | IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12213884 |
Palmqvist P et al. | IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. | 2002 | J. Immunol. | pmid:12218157 |
Sandor M et al. | A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. | 2002 | Biomaterials | pmid:12219832 |
Shiotani A et al. | Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. | 2002 | Anat. Rec. | pmid:12221720 |
Kudo O et al. | Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. | 2002 | J. Pathol. | pmid:12237882 |
Hofbauer LC et al. | High bone density due to a mutation in LDL-receptor-related protein 5. | 2002 | N. Engl. J. Med. | pmid:12240686 |
Williamson E et al. | Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. | 2002 | J. Immunol. | pmid:12244151 |
Ferrer Cañabate J et al. | [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?]. | 2002 | An Med Interna | pmid:12244784 |
Kazama JJ et al. | Circulating osteoprotegerin is not removed through haemodialysis membrane. | 2002 | Nephrol. Dial. Transplant. | pmid:12271009 |
Lee SW et al. | TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. | 2002 | J. Biochem. Mol. Biol. | pmid:12296995 |
Standal T et al. | Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. | 2002 | Blood | pmid:12351414 |
pmid:12354528 | ||||
Yang SY et al. | Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. | 2002 | Arthritis Rheum. | pmid:12355500 |
Palenzuela L et al. | Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. | 2002 | J. Med. Genet. | pmid:12362049 |
Fu Q et al. | Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. | 2002 | J. Biol. Chem. | pmid:12364326 |
Rogers A et al. | Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12364420 |
Romas E et al. | Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. | 2002 | Am. J. Pathol. | pmid:12368214 |
Rude RK et al. | Magnesium deficiency: effect on bone and mineral metabolism in the mouse. | 2003 | Calcif. Tissue Int. | pmid:12370796 |
David JP et al. | JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. | 2002 | J. Cell. Sci. | pmid:12376563 |
Jones DH et al. | Role of RANKL and RANK in bone loss and arthritis. | 2002 | Ann. Rheum. Dis. | pmid:12379618 |
Gravallese EM | Bone destruction in arthritis. | 2002 | Ann. Rheum. Dis. | pmid:12379632 |
Abrahamsen B et al. | Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. | 2003 | Calcif. Tissue Int. | pmid:12384814 |
Suda T et al. | [Merger of bone biology and immunology]. | 2002 | Tanpakushitsu Kakusan Koso | pmid:12385106 |
Nagasawa T et al. | LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. | 2002 | Clin. Exp. Immunol. | pmid:12390325 |
Cremer I et al. | Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. | 2002 | Blood | pmid:12393586 |
Giuliani N et al. | Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. | 2002 | Blood | pmid:12393684 |
Liao EY et al. | Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. | 2002 | J. Endocrinol. Invest. | pmid:12398237 |
Okada Y et al. | Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. | 2002 | Endocr. J. | pmid:12402981 |
Jung K et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. | 2002 Jul-Sep | Int. J. Biol. Markers | pmid:12408468 |
Yamada T et al. | Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. | 2003 | Blood | pmid:12411305 |
Roodman GD | Role of the bone marrow microenvironment in multiple myeloma. | 2002 | J. Bone Miner. Res. | pmid:12412796 |
Hegedus D et al. | Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. | 2002 | J. Bone Miner. Res. | pmid:12412803 |
Zhao S et al. | MLO-Y4 osteocyte-like cells support osteoclast formation and activation. | 2002 | J. Bone Miner. Res. | pmid:12412815 |
Hu Y and Yu S | Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. | 2002 | Zhonghua Bing Li Xue Za Zhi | pmid:12419159 |
Sezer O et al. | RANK ligand and osteoprotegerin in myeloma bone disease. | 2003 | Blood | pmid:12424190 |
Stejskal D et al. | Osteoprotegerin, RANK, RANKL. | 2001 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:12426773 |
Stejskal D et al. | Osteoprotegerin and bone density. | 2001 | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | pmid:12426776 |
Lubberts E et al. | Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. | 2002 | Arthritis Rheum. | pmid:12428250 |
Crotti TN et al. | Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. | 2002 | Ann. Rheum. Dis. | pmid:12429533 |
Hofbauer LC and Schoppet M | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12432053 |
Liegibel UM et al. | Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. | 2002 | J. Exp. Med. | pmid:12438430 |
Bolon B et al. | Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. | 2002 | Cell. Mol. Life Sci. | pmid:12440777 |
Yamashita T et al. | Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. | 2002 | Endocrinology | pmid:12446599 |
Shimizu-Ishiura M et al. | Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. | 2002 | J Electron Microsc (Tokyo) | pmid:12455916 |
Liu D et al. | Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. | 2003 | Int. J. Mol. Med. | pmid:12469211 |
Cho CH and Nuttall ME | Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. | 2002 | Expert Opin. Ther. Targets | pmid:12472380 |
Hasegawa T et al. | Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. | 2002 | J. Periodont. Res. | pmid:12472833 |
Avbersek-Luznik I et al. | Increased levels of osteoprotegerin in hemodialysis patients. | 2002 | Clin. Chem. Lab. Med. | pmid:12476941 |
Buckley KA et al. | Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. | 2002 | Bone | pmid:12477572 |
McCauley LK and Nohutcu RM | Mediators of periodontal osseous destruction and remodeling: principles and implications for diagnosis and therapy. | 2002 | J. Periodontol. | pmid:12479643 |
Bolon B et al. | Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. | 2002 | Arthritis Rheum. | pmid:12483715 |
Golmia RP et al. | Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacós et al. | 2002 | Arthritis Rheum. | pmid:12483748 |
Toraldo G et al. | IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. | 2003 | Proc. Natl. Acad. Sci. U.S.A. | pmid:12490655 |
Choi BK et al. | Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. | 2003 | Infect. Immun. | pmid:12496170 |
Bengtsson AK and Ryan EJ | Immune function of the decoy receptor osteoprotegerin. | 2002 | Crit. Rev. Immunol. | pmid:12498383 |
Chagraoui H et al. | Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. | 2003 | Blood | pmid:12506018 |
Lee Y et al. | Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. | 2003 | J. Orthop. Res. | pmid:12507581 |
Sabokbar A et al. | Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. | 2003 | J. Orthop. Res. | pmid:12507582 |
Elhasid R et al. | Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. | 2003 | Am. J. Hematol. | pmid:12508266 |
Haynes DR et al. | Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. | 2003 | Rheumatology (Oxford) | pmid:12509625 |
Takayanagi H | [Cross-talk between immune and skeletal systems]. | 2002 | Nippon Rinsho | pmid:12510352 |
Spyrou P et al. | Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. | 2002 | Clin Oral Implants Res | pmid:12519337 |
Berenson JR | Advances in the biology and treatment of myeloma bone disease. | 2002 | Semin. Oncol. | pmid:12520479 |
Woo KM et al. | Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. | 2002 | Exp. Mol. Med. | pmid:12526098 |
Kanematsu M et al. | [Effects of gravity on the gene expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor]. | 1999 | Biol. Sci. Space | pmid:12532992 |
Katavić V et al. | Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. | 2003 | J. Immunol. | pmid:12538719 |
Clohisy D | Cellular mechanisms of osteolysis. | 2003 | J Bone Joint Surg Am | pmid:12540662 |
Vanderkerken K et al. | Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. | 2003 | Cancer Res. | pmid:12543775 |
Kato I et al. | TRANCE together with IL-7 induces pre-B cells to proliferate. | 2003 | Eur. J. Immunol. | pmid:12548564 |
Sordillo EM and Pearse RN | RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. | 2003 | Cancer | pmid:12548579 |
Oyajobi BO and Mundy GR | Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. | 2003 | Cancer | pmid:12548580 |
Croucher PI et al. | Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. | 2003 | Cancer | pmid:12548581 |
Lipton A | Bisphosphonates and metastatic breast carcinoma. | 2003 | Cancer | pmid:12548585 |
Demers LM | Bone markers in the management of patients with skeletal metastases. | 2003 | Cancer | pmid:12548589 |
Body JJ et al. | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. | 2003 | Cancer | pmid:12548591 |
Kanematsu M et al. | [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. | 2000 | Biol. Sci. Space | pmid:12561872 |
Buckley KA and Fraser WD | Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. | 2002 | Ann. Clin. Biochem. | pmid:12564836 |
Xing L et al. | Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. | 2003 | J. Bone Miner. Res. | pmid:12568403 |
Cao J et al. | Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. | 2003 | J. Bone Miner. Res. | pmid:12568404 |
Johnson-Pais TL et al. | Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. | 2003 | J. Bone Miner. Res. | pmid:12568416 |
Clohisy JC et al. | RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. | 2003 | J. Orthop. Res. | pmid:12568950 |
Yu Q et al. | Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. | 2003 | J. Immunol. | pmid:12574344 |
Rifas L et al. | Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. | 2003 | J. Cell. Biochem. | pmid:12577299 |
Gordeladze JO and Reseland JE | A unified model for the action of leptin on bone turnover. | 2003 | J. Cell. Biochem. | pmid:12577304 |
Fahrleitner A et al. | Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. | 2003 | Bone | pmid:12584041 |
Lanzi R et al. | GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. | 2003 | Eur. J. Endocrinol. | pmid:12590637 |
Lubberts E et al. | IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. | 2003 | J. Immunol. | pmid:12594294 |
Stajszczyk M | [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. | 2002 | Pol. Arch. Med. Wewn. | pmid:12600190 |
Fahrleitner A et al. | Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. | 2002 | Wien. Klin. Wochenschr. | pmid:12602117 |
Shipman CM and Croucher PI | Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. | 2003 | Cancer Res. | pmid:12615702 |
Hamzei M et al. | Osteoclast stimulating and differentiating factors in human cholesteatoma. | 2003 | Laryngoscope | pmid:12616193 |
Siggelkow H et al. | Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. | 2003 | J. Bone Miner. Res. | pmid:12619938 |
Wiethe C et al. | Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. | 2003 | J. Immunol. | pmid:12626542 |
Ueland T et al. | Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12629078 |
Schoppet M et al. | Increased osteoprotegerin serum levels in men with coronary artery disease. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12629080 |
Han W et al. | Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. | 2003 | Biotechnol. Appl. Biochem. | pmid:12630898 |
Koshihara Y et al. | Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. | 2003 | J. Endocrinol. | pmid:12630919 |
Alvarez L et al. | Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. | 2003 | Arthritis Rheum. | pmid:12632438 |
Bord S et al. | The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. | 2003 | Bone | pmid:12633785 |
Smith MD et al. | Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. | 2003 | Ann. Rheum. Dis. | pmid:12634226 |